keyword
MENU ▼
Read by QxMD icon Read
search

biliary tract cancer

keyword
https://www.readbyqxmd.com/read/28216138/clinicopathologic-characteristics-of-young-patients-with-gallbladder-cancer
#1
Sung-Im Do, Hyoun Wook Lee, Jin Hee Sohn, Kyungeun Kim
Gallbladder cancer is the most common biliary tract cancer and the fifth most common cancer of the digestive system. However, the clinicopathologic features of gallbladder cancer in young Korean patients have not been studied. This study included 101 consecutive cases of gallbladder cancer that underwent cholecystectomy at Kangbuk Samsung Hospital from December 1990 to March 2011. The patients were divided into two groups by age at initial diagnosis of gallbladder cancer: a young patient group aged less than 45 years and an old patient group aged 45 or older...
December 29, 2016: Pathology, Research and Practice
https://www.readbyqxmd.com/read/28214200/concurrent-met-copy-number-gain-and-kras-mutation-is-a-poor-prognostic-factor-in-pancreatobiliary-subtype-ampullary-cancers
#2
Mi Jung Kwon, Jeong Won Kim, Jang Yong Jeon, Eun Sook Nam, Seong Jin Cho, Hye-Rim Park, Soo Kee Min, Jinwon Seo, Kyueng-Whan Min, Ji-Young Choe, Hye Kyung Lee
Hepatocyte growth factor (HGF) and MET are candidates of targeted therapies for cancer patients. Although MET and HGF are commonly expressed in biliary tract cancers, their expression and gene copy number status and their association with KRAS mutations have not been investigated in pancreatobiliary-type ampullary adenocarcinomas (A-ACs), one of the aggressive periampullary cancers. MET and HGF expressions and MET copy number status were examined by performing immunohistochemistry (IHC) and silver in situ hybridization (SISH) in 62 surgically resected, paraffin-embedded tumors, respectively...
January 11, 2017: Pathology, Research and Practice
https://www.readbyqxmd.com/read/28212293/targeting-angiogenesis-in-biliary-tract-cancers-an-open-option
#3
REVIEW
Valeria Simone, Oronzo Brunetti, Luigi Lupo, Mario Testini, Eugenio Maiorano, Michele Simone, Vito Longo, Christian Rolfo, Marc Peeters, Aldo Scarpa, Amalia Azzariti, Antonio Russo, Domenico Ribatti, Nicola Silvestris
Biliary tract cancers (BTCs) are characterized by a bad prognosis and the armamentarium of drugs for their treatment is very poor. Although the inflammatory status of biliary tract represents the first step in the cancerogenesis, the microenvironment also plays a key role in the pathogenesis of BTCs, promoting tumor angiogenesis, invasion and metastasis. Several molecules, such as vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF), are involved in the angiogenesis process and their expression on tumor samples has been explored as prognostic marker in both cholangiocarcinoma and gallbladder cancer...
February 15, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28188670/a-randomized-phase-ii-trial-of-personalized-peptide-vaccine-with-low-dose-cyclophosphamide-in-biliary-tract-cancer
#4
Takahisa Shirahama, Daisuke Muroya, Satoko Matsueda, Akira Yamada, Shigeki Shichijo, Masayasu Naito, Takuto Yamashita, Shinjiro Sakamoto, Koji Okuda, Kyogo Itoh, Tetsuro Sasada, Shigeru Yutani
Since the prognosis of advanced biliary tract cancer (aBTC) still remains very poor, new therapeutic approaches, including immunotherapies, need to be developed. In the current study, we conducted an open-label randomized phase II study to test whether low dose cyclophosphamide (CPA) could improve antigen-specific immune responses and clinical efficacy of personalized peptide vaccination (PPV) in 49 previously treated aBTC patients. Patients with aBTC refractory to at least one regimen of chemotherapies were randomly assigned to receive PPV with low dose CPA (100 mg/ day for 7 days before vaccination) (PPV/CPA, n=24) or PPV alone (n=25)...
February 11, 2017: Cancer Science
https://www.readbyqxmd.com/read/28188502/efficacy-of-preoperative-portal-vein-embolization-among-patients-with-hepatocellular-carcinoma-biliary-tract-cancer-and-colorectal-liver-metastases-a-comparative-study-based-on-single-center-experience-of-319-cases
#5
Suguru Yamashita, Yoshihiro Sakamoto, Satoshi Yamamoto, Nobuyuki Takemura, Kiyohiko Omichi, Hiroji Shinkawa, Kazuhiro Mori, Junichi Kaneko, Nobuhisa Akamatsu, Junichi Arita, Kiyoshi Hasegawa, Norihiro Kokudo
BACKGROUND: Efficacy of preoperative portal vein embolization (PVE) has been established; however, differences of outcomes among diseases, including hepatocellular carcinoma (HCC), biliary tract cancer (BTC), and colorectal liver metastases (CLM), are unclear. METHODS: Subjects included patients in a prospectively collected database undergoing PVE (from 1995 to 2013). A future liver remnant (FLR) volume ≥40% is the minimal requirement for patients with an indocyanine green retention rate at 15 min (ICGR15) <10%, and stricter criteria (FLR volume ≥50%) have been applied for patients with 20% > ICGR15 ≥ 10%...
February 10, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28179351/a-multicenter-phase-ii-study-of-gemcitabine-plus-s-1-chemotherapy-for-advanced-biliary-tract-cancer
#6
Shiho Arima, Kyoko Shimizu, Tomoyoshi Okamoto, Masao Toki, Yutaka Suzuki, Naohiro Okano, Daisuke Naruge, Kirio Kawai, Takaaki Kobayashi, Akiyoshi Kasuga, Hiroshi Kitamura, Atuko Takasu, Fumio Nagashima, Masanori Sugiyama, Junji Furuse
BACKGROUND: Gemcitabine (GEM) plus cisplatin (CDDP) chemotherapy has been used worldwide as the standard first-line treatment for advanced biliary tract cancer (BTC). A phase II trial has also suggested promising activity of GEM plus S-1 chemotherapy against advanced BTC. The aim of this study was to evaluate the efficacy and safety of GEM plus S-1 chemotherapy in patients with advanced BTC. PATIENTS AND METHODS: The eligibility criteria were as follows: histologically-proven BTC, unresectable or recurrent disease, ECOG performance status (PS) 0-1 regardless of previous treatment...
2017: Anticancer Research
https://www.readbyqxmd.com/read/28166534/prognostic-factors-associated-with-preoperative-clinicophysiological-outcomes-of-distal-cholangiocarcinoma
#7
Shuji Suzuki, Hideki Kajiyama, Mitsugi Shimoda, Jiro Shimazaki, Nobusada Koike, Nobuhiko Harada
BACKGROUND/AIMS: Although biliary tract cancer is generally associated with a high mortality rate, patients with distal cholangiocarcinoma have better prognoses, compared to those with periampullary cancer. This study aimed to determine the preoperative clinicophysiological factors predictive of survival and recurrence in patients with distal cholangiocarcinoma. METHODS: Forty-five patients (34 men) with distal cholangiocarcinoma who underwent pancreaticoduodenectomy between 2005 and 2013 were examined retrospectively at our center and associated hospitals...
February 7, 2017: Digestive Surgery
https://www.readbyqxmd.com/read/28161931/prognostic-factors-and-scoring-model-for-survival-in-metastatic-biliary-tract-cancer
#8
Hyung Soon Park, Ji Soo Park, You Jin Chun, Yun Ho Roh, Jieun Moon, Hong Jae Chon, Hye Jin Choi, Joon Seong Park, Dong Ki Lee, Se-Joon Lee, Dong Sup Yoon, Hei-Cheul Jeung
Purpose: Metastatic biliary tract cancer (mBTC) has a dismal prognosis. In this study, an independent dataset of patients with mBTC was used to implement and validate a routine clinico-laboratory parameter-based scoring model for risk group identification. Materials and Methods: From September 2006 to February 2015, 482 patients with mBTC were assigned randomly (ratio, 7:3) into investigational (n = 340) and validation datasets (n = 142). The continuous variables were dichotomized using a normal range or the best cutoff values determined using the Contal and O'Quigley statistical methods...
February 6, 2017: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://www.readbyqxmd.com/read/28160269/infections-in-cancer-patients-with-solid-tumors-a-review
#9
REVIEW
Kenneth V I Rolston
Solid tumors are much more common than hematologic malignancies. Although severe and prolonged neutropenia is uncommon, several factors increase the risk of infection in patients with solid tumors, and the presence of multiple risk factors in the same patient is not uncommon. These include obstruction (most often caused by progression of the tumor), disruption of natural anatomic barriers such as the skin and mucosal surfaces, and treatment-related factors such as chemotherapy, radiation, diagnostic and/or therapeutic surgical procedures, and the increasing use of medical devices such as various catheters, stents, and prostheses...
February 3, 2017: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/28156572/end-of-life-care-decisions-using-korean-advance-directives-among-cancer-patient-caregiver-dyads
#10
Shinmi Kim, JinShil Kim
: 11 Background: The Korean advance directives (K-ADs) consist of a value statement, treatment directives (cardiopulmonary resuscitation [CPR], preferences for artificial ventilation, tube feeding, and hospice care). K-ADs can facilitate a patient's decision-making for end-of-life (EOL) care. This study aims to examine the extent to which patient-caregiver dyads agreed on decisions for EOL care using the K-ADs. METHODS: Using a descriptive study design, 81 cancer patients were invited to participate...
October 9, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28152549/circulating-copper-and-zinc-levels-and-risk-of-hepatobiliary-cancers-in-europeans
#11
Magdalena Stepien, David J Hughes, Sandra Hybsier, Christina Bamia, Anne Tjønneland, Kim Overvad, Aurélie Affret, Mathilde His, Marie-Christine Boutron-Ruault, Verena Katzke, Tilman Kühn, Krasimira Aleksandrova, Antonia Trichopoulou, Pagona Lagiou, Phlippos Orfanos, Domenico Palli, Sabina Sieri, Rosario Tumino, Fulvio Ricceri, Salvatore Panico, H B As Bueno-de-Mesquita, Petra H Peeters, Elisabete Weiderpass, Cristina Lasheras, Catalina Bonet Bonet, Elena Molina-Portillo, Miren Dorronsoro, José María Huerta, Aurelio Barricarte, Bodil Ohlsson, Klas Sjöberg, Mårten Werner, Dmitry Shungin, Nick Wareham, Kay-Tee Khaw, Ruth C Travis, Heinz Freisling, Amanda J Cross, Lutz Schomburg, Mazda Jenab
BACKGROUND: Copper and zinc are essential micronutrients and cofactors of many enzymatic reactions that may be involved in liver-cancer development. We aimed to assess pre-diagnostic circulating levels of copper, zinc and their ratio (Cu/Zn) in relation to hepatocellular carcinoma (HCC), intrahepatic bile duct (IHBD) and gall bladder and biliary tract (GBTC) cancers. METHODS: A nested case-control study was conducted within the European Prospective Investigation into Cancer and Nutrition cohort...
February 2, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28130841/dmbt1-expression-in-biliary-carcinogenesis-with-correlation-of-clinicopathological-data
#12
Benjamin Goeppert, Stephanie Roessler, Natalia Becker, Manuela Zucknick, Monika Nadja Vogel, Arne Warth, Anita Pathil-Warth, Arianeb Mehrabi, Peter Schirmacher, Jan Mollenhauer, Marcus Renner
AIMS: Deleted in Malignant Brain Tumors 1 (DMBT1) exerts functions in the regulation of epithelial differentiation and inflammation and has been proposed as tumor suppressor. Since chronic inflammation is a hallmark of cholangiocarcinogenesis, the aim of the study was to investigate the expression of DMBT1 in biliary tract cancer (BTC) and to correlate the expression with clinicopathological data. METHODS AND RESULTS: The expression of DMBT1 protein was examined immunohistochemically in 157 BTC patients (41 intrahepatic (ICC), 60 extrahepatic cholangiocarcinomas (ECC), and 56 adenocarcinomas of the gallbladder (GBAC))...
January 28, 2017: Histopathology
https://www.readbyqxmd.com/read/28124197/gemcitabine-and-s-1-versus-gemcitabine-and-cisplatin-treatment-in-patients-with-advanced-biliary-tract-cancer-a-multicenter-retrospective-study
#13
Naminatsu Takahara, Hiroyuki Isayama, Yousuke Nakai, Takashi Sasaki, Kazunaga Ishigaki, Kei Saito, Dai Akiyama, Rie Uchino, Suguru Mizuno, Hiroshi Yagioka, Hirofumi Kogure, Osamu Togawa, Saburo Matsubara, Yukiko Ito, Nobuo Toda, Minoru Tada, Kazuhiko Koike
Objective This study aimed to compare the safety and efficacy of the combination therapy of gemcitabine and S-1 (GS) versus gemcitabine and cisplatin (GC) in patients with advanced biliary tract cancer (BTC). Methods In this multicenter retrospective cohort study, a total of 212 patients with advanced BTC receiving GS (n = 125) or GC (n = 87) between July 2006 and August 2015 were analyzed. The primary endpoint was overall survival (OS). The secondary endpoints were progression-free survival (PFS), objective tumor response, and safety...
January 26, 2017: Investigational New Drugs
https://www.readbyqxmd.com/read/28123600/activation-or-suppression-of-the-immune-response-mediators-in-biliary-tract-cancer-btc-patients-a-systematic-review-and-meta-analysis
#14
Ying Wang, Min Ding, Qian Zhang, Jinghan Wang, Xijing Yang, Fuping Zhou, Linfang Li, Zhengang Yuan, Huajun Jin, Qijun Qian
Background: Infiltration of immune cells and immune microenvironment determine the proliferative activity of the tumor and metastasis. The aim of this study was to analyze the influence of activation or suppression of the immune response mediators on the prognosis of biliary tract cancer (BTC). Methods: We searched Pubmed, Web of Science, Embase and The Cochrane Library for relevant literatures until June 2016. The quality of studies was assessed by QUADAS-2 and NOS tools. Forest and funnel plots and all statistical analyses were generated by using Review Manager 5...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28118609/the-clinical-value-of-lncrna-neat1-in-digestive-system-malignancies-a-comprehensive-investigation-based-on-57-microarray-and-rna-seq-datasets
#15
Dan-Dan Xiong, Zhen-Bo Feng, Wei-Luan Cen, Jing-Jing Zeng, Lu Liang, Rui-Xue Tang, Xiao-Ning Gan, Hai-Wei Liang, Zu-Yun Li, Gang Chen, Dian-Zhong Luo
This comprehensive investigation was performed to evaluate the expression level and potential clinical value of NEAT1 in digestive system malignancies. A total of 57 lncRNA datasets of microarray or RNA-seq and 5 publications were included. The pooled standard mean deviation (SMD) indicated that NEAT1 was down-regulated in esophageal carcinoma (ESCA, SMD = -0.35, 95% CI: -0.5~-0.20, P < 0.0001) and hepatocellular carcinoma (HCC, SMD = -0.47, 95% CI: -0.60~-0.34, P < 0.0001), while in pancreatic cancer (PC), NEAT1 was up-regulated (SMD = 0...
January 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/28111425/ca19-9-or-cea-decline-after-the-first-cycle-of-treatment-predicts-survival-in-advanced-biliary-tract-cancer-patients-treated-with-s-1-and-cisplatin-chemotherapy
#16
Dae-Won Lee, Seock-Ah Im, Yu Jung Kim, Yaewon Yang, Jiyoung Rhee, Im Il Na, Kyung-Hun Lee, Tae-Yong Kim, Sae-Won Han, In Sil Choi, Do-Youn Oh, Jee Hyun Kim, Tae-You Kim, Yung-Jue Bang
Purpose: While tumor markers (CA 19-9 and CEA) can aid in the diagnosis of biliary tract cancer, their prognostic role has not been clearly elucidated. Therefore, this study was conducted to evaluate the prognostic role of tumor markers and tumor marker change in patients with advanced biliary tract cancer. Materials and Methods: Patients with pathologically proven metastatic or relapsed biliary tract cancer who were treated in a phase II trial of first line S-1 and cisplatin chemotherapy were enrolled...
January 18, 2017: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://www.readbyqxmd.com/read/28101354/histological-complete-response-in-a-patient-with-advanced-biliary-tract-cancer-treated-by-gemcitabine-cisplatin-s-1-combination-chemotherapy-a-case-report
#17
Tokuhiro Matsubara, Tsutomu Nishida, Yoshito Tomimaru, Masashi Yamamoto, Shiro Hayashi, Sachiko Nakajima, Koji Fukui, Keizo Dono, Shiro Adachi, Tatsuya Ioka, Masashi Kanai, Masami Inada
A 68-year-old woman was referred to our hospital with increased levels of biliary enzymes. On imaging, the patient was diagnosed with unresectable intrahepatic biliary tract cancer (BTC) with invasion of the portal vein and para-aortic lymph node metastasis (cT3N1M1, cStage IVb) and underwent endoscopic biliary drainage for the biliary stricture prior to therapy. The patient was subsequently enrolled in a phase III randomized trial (UMIN000014371/NCT02182778) and randomly assigned to receive gemcitabine/cisplatin/S-1 (GCS) combination therapy intravenously at doses of 1,000 or 25 mg/m(2) on day 1 and orally twice daily at a dose of 80 mg/m(2) on days 1-7 every 2 weeks...
December 2016: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28100416/a-retrospective-analysis-of-the-clinical-effects-of-neoadjuvant-combination-therapy-with-full-dose-gemcitabine-and-radiation-therapy-in-patients-with-biliary-tract-cancer
#18
S Kobayashi, A Tomokuni, K Gotoh, H Takahashi, H Akita, S Marubashi, T Yamada, T Teshima, K Fukui, Y Fujiwara, M Sakon
PURPOSE: This study aims to evaluate survival and the objective response to neoadjuvant combination therapy with gemcitabine and radiation therapy in patients with biliary tract cancer. METHODS: The chemoradiation therapy regimen consisted of 3 cycles of full-dose gemcitabine (1000 mg/m(2) at days 1, 8, and 15, every 4 weeks) with 50-60 Gy radiation. We compared 27 patients who received neoadjuvant chemoradiation therapy and 79 patients who were treated without neoadjuvant therapy...
January 11, 2017: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28090501/clinical-implications-of-apex1-and-jagged1-as-chemoresistance-factors-in-biliary-tract-cancer
#19
Hong-Beum Kim, Won Jin Cho, Nam Gyu Choi, Sung-Soo Kim, Jun Hee Park, Hee-Jeong Lee, Sang Gon Park
PURPOSE: Biliary cancer is a highly malignant neoplasm with poor prognosis and most patients need to undergo palliative chemotherapy, however major clinical problem associated with the use of chemotherapy is chemoresistance. So far, we aimed at investigating clinical implications of apurinic/apyrimidinic endodeoxyribonuclease 1 (APEX1) and Jagged1 as chemoresistance factors in biliary tract cancer. METHODS: We used 5 human biliary tract cancer cell lines (SNU-245, SNU-308, SNU-478, SNU-1079, and SNU-1196), and investigated the chemosensitivity of APEX1 and Jagged1 through 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay and Western blot...
January 2017: Annals of Surgical Treatment and Research
https://www.readbyqxmd.com/read/28086990/the-efficacy-of-fluoropyrimidine-based-adjuvant-chemotherapy-on-biliary-tract-cancer-after-r0-resection
#20
Young Saing Kim, Chi-Young Jeong, Haa-Na Song, Tae Hyo Kim, Hong Jun Kim, Young-Joon Lee, Soon Chan Hong
BACKGROUND: The optimal treatment strategy for biliary tract cancer (BTC) after curative-intent resection remains controversial. The purpose of this study was to evaluate the efficacy of fluoropyrimidine-based adjuvant chemotherapy for BTC patients undergoing microscopically margin-negative (R0) resection. METHODS: We retrospectively analyzed the clinical data of BTC patients who underwent curative-intent R0 resection. Patients were eligible if they received either fluoropyrimidine-based adjuvant chemotherapy or observation after R0 resection...
January 13, 2017: Chinese Journal of Cancer
keyword
keyword
85541
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"